ACM
BIIB icon

Accipiter Capital Management’s Biogen BIIB Stock Holding History

Accipiter Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-76,156
Closed -$19.8M – 8
2016
Q1 		$19.8M Buy
76,156
+1,247
+2% +$329K 11.33% 3
2015
Q4 		$22.9M Buy
+74,909
New +$21.5M 12.54% 3
2014
Q3 		$4.96M Buy
15,000
+5,462
+57% +$1.8M 8.9% 7
2014
Q2 		$3.01M Buy
+9,538
New +$2.87M 5.55% 9

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Accipiter Capital Management's BIIB Position: Q2 2016 in Review

Accipiter Capital Management sold out of Biogen (BIIB) in Q2 2016, closing a stake of 76,156 shares — an estimated $19.8M sold.

Accipiter Capital Management first reported a position in BIIB in Q2 2014 and held it in 4 quarters. The position peaked at $22.9M in Q4 2015. 966 funds tracked by Wall St. Rank hold BIIB as of Q2 2016.

  • Accipiter Capital Management reported no remaining Biogen position as of Q2 2016 after selling out during the quarter.
  • Accipiter Capital Management sold 76,156 Biogen shares in Q2 2016, an estimated $19.8M.
  • Accipiter Capital Management first reported a position in Biogen in Q2 2014 and held it in 4 quarters.
  • Accipiter Capital Management's Biogen position peaked at $22.9M in Q4 2015.
  • 966 funds tracked by Wall St. Rank held Biogen as of Q2 2016.

Based on Accipiter Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.